3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
10
Salivary Gland Neoplasms
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Hematologic Neoplasms
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Hemangiosarcoma
1
HER2-positive Metastatic Breast Cancer
1
HER2-positive Breast Cancer
1
HER2-Positive Primary Breast Cancer
1
Glioma
1
Interventions
fludarabine
27
Azacitidine
26
venetoclax
23
Cyclophosphamide
22
Specimen Handling
21
fludarabine phosphate
17
Biopsy
16
Whole-Body Irradiation
15
Mycophenolic Acid
15
Busulfan
15
Melphalan
14
Cytarabine
14
Tacrolimus
13
Granulocyte Colony-Stimulating Factor
12
Decitabine
11
Stem Cell Transplantation
10
Injections
10
Cyclosporine
10
decitabine and cedazuridine drug combination
9
Sirolimus
9
Filgrastim
9
Peripheral Blood Stem Cell Transplantation
8
Thiotepa
7
X-Rays
6
Idarubicin
6
ruxolitinib
5
Cyclosporins
5
Cladribine
5
Methotrexate
4
Magnetic Resonance Spectroscopy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Myelodysplastic Syndromes
×
Ado-Trastuzumab Emtansine
×
90 days
×
Clear all
No trials found.